NCT00069849终止2 期
A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's Disease
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- Abbott
- 入组人数
- 64
- 试验地点
- 8
- 主要终点
- MMSE
研究概览
简要总结
The purpose of this study is to compare the safety and efficacy of 2 mg, 4 mg, and 20 mg of ABT-089 BID to placebo in adults with Alzheimer's disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 50 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Current diagnosis of probable Alzheimer's disease.
- •ADAS-cog score of at least 12 and MMSE score of 10 to
- •Non-smoker
- •Must have legally authorized representative and a reliable caregiver. The caregiver and legally authorized representative may be the same person.
- •Fluent in English.
排除标准
- •Use of cholinesterase inhibitors or any other drugs to treat Alzheimer's disease in the last 6 weeks.
- •Has clinically significant or uncontrolled medical condition other than Alzheimer's disease.
- •Nursing home resident.
结局指标
主要结局
MMSE
次要结局
未报告次要终点
研究者
研究点 (8)
Loading locations...
相似试验
已完成
1 期
Pharmacokinetics and Safety of the Co-administration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Healthy Chinese SubjectsHealthy VolunteerNCT02534870AbbVie18
已完成
2 期
A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexate in Subjects With Rheumatoid Arthritis Who Failed Anti-Tumor Necrosis Factor (TNF) Biologic TherapyRheumatoid ArthritisNCT01960855AbbVie276
已完成
2 期
Safety and Efficacy Study in Subjects With Diabetic Neuropathic PainDiabetic NeuralgiaDiabetic NeuropathiesDiabetic Neuropathy, PainfulDiabetic PolyneuropathyNeuralgia, DiabeticNCT00507936AbbVie (prior sponsor, Abbott)280
已完成
2 期
A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)Attention-Deficit/Hyperactivity DisorderNCT00391729Abbott221
已完成
1 期
A Multiple Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-288 in Stable Subjects With SchizophreniaSchizophreniaNCT00888693AbbVie81